JP2023543005A5 - - Google Patents
Info
- Publication number
- JP2023543005A5 JP2023543005A5 JP2023519051A JP2023519051A JP2023543005A5 JP 2023543005 A5 JP2023543005 A5 JP 2023543005A5 JP 2023519051 A JP2023519051 A JP 2023519051A JP 2023519051 A JP2023519051 A JP 2023519051A JP 2023543005 A5 JP2023543005 A5 JP 2023543005A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- pain
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063084358P | 2020-09-28 | 2020-09-28 | |
| US63/084,358 | 2020-09-28 | ||
| PCT/EP2021/076524 WO2022064043A1 (en) | 2020-09-28 | 2021-09-27 | Compounds and methods for treating pain |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023543005A JP2023543005A (ja) | 2023-10-12 |
| JP2023543005A5 true JP2023543005A5 (https=) | 2024-10-04 |
Family
ID=78085879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023519051A Pending JP2023543005A (ja) | 2020-09-28 | 2021-09-27 | 疼痛を処置するための化合物及び方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240026036A1 (https=) |
| EP (1) | EP4217388A1 (https=) |
| JP (1) | JP2023543005A (https=) |
| KR (1) | KR20230084199A (https=) |
| CN (1) | CN117279942A (https=) |
| AU (1) | AU2021350424A1 (https=) |
| BR (1) | BR112023004840A2 (https=) |
| CA (1) | CA3195380A1 (https=) |
| IL (1) | IL301548A (https=) |
| TW (1) | TW202228768A (https=) |
| WO (1) | WO2022064043A1 (https=) |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5681718A (en) | 1986-03-14 | 1997-10-28 | Celltech Limited | Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| CA2975521A1 (en) | 2001-05-30 | 2002-12-05 | Genentech, Inc. | Anti-ngf antibodies for the treatment of various disorders |
| GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
| ZA200502612B (en) | 2002-10-08 | 2007-07-25 | Rinat Neuroscience Corp | Methods for treating post-surgical pain by administering a nerve crowth factor antagonist and compositions containing the same |
| US20080187954A1 (en) | 2004-03-10 | 2008-08-07 | Lonza Ltd. | Method For Producing Antibodies |
| CA2581208A1 (en) | 2004-08-30 | 2006-03-09 | Lonza Biologics Plc. | Affinity- plus ion exchange- chromatography for purifying antibodies |
| EP2298345A3 (en) | 2005-01-24 | 2012-03-21 | MedImmune Limited | Specific binding members for NGF |
| US7691980B2 (en) | 2007-01-09 | 2010-04-06 | Bio-Rad Laboratories, Inc. | Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers |
| MX2010001395A (es) | 2007-08-10 | 2010-03-10 | Regeneron Pharma | Anticuerpos humanos de alta afinidad de factor de crecimiento de nervio humano. |
| EP2238154B1 (en) | 2008-01-18 | 2015-09-16 | Bio-Rad Laboratories, Inc. | Enhanced purification of phosphorylated and non-phosphorylated biomolecules by apatite chromatography |
| BR112012008833A2 (pt) * | 2009-10-15 | 2015-09-08 | Abbott Lab | imunoglobulinas de dominio variavel duplo e usos das mesmas |
| US9580509B2 (en) | 2011-11-07 | 2017-02-28 | Medimmune, Llc | Multispecific and multivalent binding proteins and uses thereof |
| LT3099713T (lt) * | 2014-02-02 | 2020-07-10 | Medimmune Limited | Chimerinis baltymas, sudarytas iš ngf antagonistinio domeno ir tnfa antagonistinio domeno |
| FI3863647T3 (fi) * | 2018-10-10 | 2024-03-01 | Paradigm Biopharmaceuticals Ltd | Pahanlaatuisen luustokivun hoitaminen pentosaanipolysulfaatilla |
-
2021
- 2021-09-27 KR KR1020237014327A patent/KR20230084199A/ko active Pending
- 2021-09-27 AU AU2021350424A patent/AU2021350424A1/en not_active Abandoned
- 2021-09-27 IL IL301548A patent/IL301548A/en unknown
- 2021-09-27 US US18/246,794 patent/US20240026036A1/en active Pending
- 2021-09-27 CN CN202180065320.3A patent/CN117279942A/zh active Pending
- 2021-09-27 BR BR112023004840A patent/BR112023004840A2/pt unknown
- 2021-09-27 JP JP2023519051A patent/JP2023543005A/ja active Pending
- 2021-09-27 WO PCT/EP2021/076524 patent/WO2022064043A1/en not_active Ceased
- 2021-09-27 CA CA3195380A patent/CA3195380A1/en active Pending
- 2021-09-27 EP EP21789613.3A patent/EP4217388A1/en active Pending
- 2021-09-28 TW TW110136070A patent/TW202228768A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3177024A1 (en) | Proteins binding nkg2d, cd16 and clec12a | |
| KR20220024729A (ko) | B-세포 성숙 항원을 표적으로 하는 다중특이성 항체에 대한 투여 요법 및 병용 요법 | |
| US20250051413A1 (en) | Chimeric molecules comprising il-12 agonist polypeptide | |
| EP3630838A1 (en) | Activatable anti-pdl1 antibodies, and methods of use thereof | |
| CN105705519A (zh) | 抗C-MET串联Fc双特异性抗体 | |
| AU2016329197A1 (en) | Binding molecules with modified J-chain | |
| US20230192887A1 (en) | Engineered anti-her2 bispecific proteins | |
| AU2015313827C1 (en) | Use of IL-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients | |
| US11680102B2 (en) | Anti-BAFF receptor antibodies and uses thereof | |
| WO2021143767A1 (zh) | 结合pd-1和pd-l1的双特异性抗体的制剂及其用途 | |
| CN112480259B (zh) | 抗tnfr2抗体及其用途 | |
| JP2023543005A5 (https=) | ||
| US20240124607A1 (en) | Proteins binding nkg2d, cd16, and ceacam5 | |
| TW202428608A (zh) | 抗b7h3抗體以及其使用方法 | |
| CN119768431A (zh) | Igf1r抗体 | |
| IL309107A (en) | Humanized antibodies against CLEC-1A, antigen-binding fragments thereof and their mimetics | |
| KR20220045559A (ko) | 안정화된 Ace2 변이체, 이를 이용한 Ace2-Fc 융합단백질 및 COVID-19 예방 또는 치료용 약학 조성물 | |
| US20240392035A1 (en) | Engineered anti-her2 bispecific proteins | |
| CN121293352A (zh) | 抗cmet抗体及使用方法 | |
| US20250122286A1 (en) | Antibody optimization | |
| CA3227716A1 (en) | Antibodies and igg fusion proteins with an extended half-life | |
| JP2026500752A (ja) | 抗ｂ７ｈ３抗体及びその使用方法 | |
| TW202608918A (zh) | 雙鏈構建體的配對 | |
| WO2025085610A1 (en) | Combination treatment of prostate cancers with two bispecific antibodies | |
| EP4496814A1 (en) | Combination therapy methods with t-cell engaging molecules for treatment of prostate cancer |